Cell Signaling Technology

Product Pathways - Apoptosis

TRAIL (C92B9) Rabbit mAb #3219

Applications Reactivity Sensitivity MW (kDa) Isotype
W IP IHC-P IF-IC F H Endogenous 28-30 Rabbit IgG

Applications Key:  W=Western Blotting  IP=Immunoprecipitation  IHC-P=Immunohistochemistry (Paraffin)  IF-IC=Immunofluorescence (Immunocytochemistry)  F=Flow Cytometry
Reactivity Key:  H=Human
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

TRAIL (C92B9) Rabbit mAb detects endogenous levels of total human TRAIL protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys60 of human TRAIL, within the extracellular region of the protein.

Western Blotting

Western Blotting

Western blot analysis of extract from 786-0 cells and differentiated THP-1 cells, untreated or treated overnight with LPS, using TRAIL (C92B9) Rabbit mAb.

Western Blotting

Western Blotting

Western blot analysis of extracts from HeLa cells, mock transfected or transfected with human TRAIL expression construct, using TRAIL (C92B9) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lung carcinoma using TRAIL (C92B9) Rabbit mAb.


IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human lymphoma using TRAIL (C92B9) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded 786-0 (positive, left) or HeLa (negative, right) cell pellets using TRAIL (C92B9) Rabbit mAb.

IHC-P (paraffin)

IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human tonsil using TRAIL (C92B9) Rabbit mAb in the presence of control peptide (left) or antigen-specific peptide (right).


Flow Cytometry

Flow Cytometry

Flow cytometric analysis of 786-0 cells using TRAIL (C92B9) Rabbit mAb (blue) compared to a nonspecific negative control antibody (red).

IF-IC

IF-IC

Confocal immunofluorescent analysis of 786-0 cells using TRAIL (C92B9) Rabbit mAb (green). Actin filaments have been labeled with DY-554 phalloidin (red). Blue pseudocolor = DRAQ5™ (fluorescent DNA dye).

Background

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also referred to as Apo2 ligand, first identified based on its sequence homology to TNF and Fas/Apo ligand is a member of the TNF family of cytokines and either exists as a type II membrane or soluble protein (1,2). TRAIL induces apoptosis in a variety of transformed cell lines and plays a role in anti-tumor and anti-viral immune surveillance (3). TRAIL signals via binding with death receptors DR4 (TRAIL-R1) (4) and DR5 (TRAIL-R2) (5-8) which can trigger apoptosis as well as NF-κB activation (7,9). Death domains on these receptors leads to the recruitment of a death-induced signaling complex (DISC) leading to caspase-8 and subsequent caspase-3 activation. In addition, TRAIL binds with decoy receptors DcR1 (TRAIL-R3) (10-13) and DcR2 (TRAIL-R4, TRUNDD) (14-15) which lack the functional cytoplasmic death domain antagonizing TRAIL-induced apoptosis. Osteoprotegerin (OPG) has also been identified as receptor capable of inhibiting TRAIL-induced apoptosis (16). The selectivity of soluble TRAIL at triggering apoptosis in transformed cells as compared to normal cells has led to its investigation as a potential cancer therapeutic (17-18).

  1. Wiley, S.R. et al. (1995) Immunity 3, 673-82.
  2. Pitti, R.M. et al. (1996) J Biol Chem 271, 12687-90.
  3. Almasan, A. and Ashkenazi, A. Cytokine Growth Factor Rev 14, 337-48.
  4. Pan, G. et al. (1997) Science 276, 111-3.
  5. Walczak, H. et al. (1997) EMBO J 16, 5386-97.
  6. MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
  7. Chaudhary, P.M. et al. (1997) Immunity 7, 821-30.
  8. Schneider, P. et al. (1997) FEBS Lett 416, 329-34.
  9. Shetty, S. et al. (2002) Apoptosis 7, 413-20.
  10. Sheridan, J.P. et al. (1997) Science 277, 818-21.
  11. Degli-Esposti, M.A. et al. (1997) J Exp Med 186, 1165-70.
  12. MacFarlane, M. et al. (1997) J Biol Chem 272, 25417-20.
  13. Schneider, P. et al. (1997) FEBS Lett 416, 329-34.
  14. Pan, G. et al. (1998) FEBS Lett 424, 41-5.
  15. Marsters, S.A. et al. (1997) Curr Biol 7, 1003-6.
  16. Kelley, S.K. et al. (2001) J Pharmacol Exp Ther 299, 31-8.
  17. Walczak, H. et al. (1999) Nat Med 5, 157-63.
  18. Ashkenazi, A. et al. (1999) J Clin Invest 104, 155-62.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products